Decentralized Clinical Trials Involving Biologics: Unique Challenges
Decentralized clinical trial (DCT) modalities continue to transform the way we conduct clinical research. One surprising area: studies involving genetically modified biologics.
In this webinar, you’ll find out what FDA says about DCTs and biologics, and what this means in practice. Dr. Daniel Eisenman provides a biosafety perspective on these types of studies, explaining the unique risks and important considerations for ensuring safe, responsible trial conduct.
Learning Objectives:
-
Describe key ways biologics research differs from small molecule research
- Summarize what FDA guidance says about DCTs involving biologics
- Discuss ways to address the unique challenge of biologics in DCTs
Presented By
Daniel Eisenman
PhD, RBP, SM(NRCM), CBSP
Executive Director, Biosafety Services
Advarra
Meagan Vaughn
PhD, RAC
Associate Clinical Director, Clinical Development
Krystal Biotech
Jennifer Abeles
DO
Assistant Clinical Professor, Internal Medicine and Pediatrics
Conventus Site Medical Director for UBMD
n/a
n/a
n/a
n/a
DATE: June 17, 2021
Time: 1 pm ET | 10 am PT
Duration: 1 hour